TEJ 1704
Alternative Names: J2H-1704Latest Information Update: 01 Apr 2021
At a glance
- Originator J2H Biotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 23 Mar 2021 Preclinical trials in Amyotrophic lateral sclerosis in South Korea (PO) prior to March 2021 (J2H Biotech pipeline, March 2021)